Literature DB >> 16453255

Predictors of immunity after a major serogroup W-135 meningococcal disease epidemic, Burkina Faso, 2002.

Pratima L Raghunathan1, Joshua D Jones, Sylvestre R M Tiendrebéogo, Idrissa Sanou, Lassana Sangaré, Seni Kouanda, Moumouni Dabal, Clement Lingani, Cheryl M Elie, Scott Johnson, Mary Ari, Joseph Martinez, Julie Chatt, Kassim Sidibe, Susanna Schmink, Leonard W Mayer, M Kader Kondé, Mamoudou H Djingarey, Tanja Popovic, Brian D Plikaytis, George M Carlone, Nancy Rosenstein, Montse Soriano-Gabarró.   

Abstract

BACKGROUND: The African meningitis belt undergoes recurrent epidemics caused by Neisseria meningitidis serogroup A. During 2002, Burkina Faso documented the first large serogroup W-135 (NmW-135) meningococcal disease epidemic. To understand the emergence of NmW-135, we investigated meningococcal carriage and immunity.
METHODS: Immediately after Burkina Faso's epidemic, we conducted a cross-sectional survey of meningococcal carriage and seroprevalence in an epidemic and a nonepidemic district. We identified predictors of elevated NmW-135 serum bactericidal activity (SBA), a functional correlate of protection, using multivariate logistic regression.
RESULTS: The NmW-135 carriage rate was 25.2% in the epidemic district and 3.4% in the nonepidemic district (P<.0001). Compared with residents of the nonepidemic district, those of the epidemic district had higher geometric mean titers of NmW-135 SBA (P<.0001). NmW-135 SBA titers>or=1:8, an estimated protective threshold, were observed in 60.4% and 34.0% of residents of the epidemic and nonepidemic district, respectively (P=.0002). In a multivariate model, current NmW-135 carriage, age, and residence in the epidemic district were independent predictors of having an NmW-135 SBA titer>or=1:8.
CONCLUSIONS: Extensive NmW-135 carriage and transmission in the epidemic area caused residents to acquire natural immunity. Serial carriage and seroprevalence surveys could establish the duration of immunity in the population. The persistent circulation of NmW-135 underscores the potential for periodic NmW-135 epidemics in Africa.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16453255     DOI: 10.1086/499822

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  21 in total

1.  Baseline meningococcal carriage in Burkina Faso before the introduction of a meningococcal serogroup A conjugate vaccine.

Authors:  Paul A Kristiansen; Fabien Diomandé; Stanley C Wei; Rasmata Ouédraogo; Lassana Sangaré; Idrissa Sanou; Denis Kandolo; Pascal Kaboré; Thomas A Clark; Abdoul-Salam Ouédraogo; Ki Ba Absatou; Charles D Ouédraogo; Musa Hassan-King; Jennifer Dolan Thomas; Cynthia Hatcher; Mamoudou Djingarey; Nancy Messonnier; Marie-Pierre Préziosi; Marc LaForce; Dominique A Caugant
Journal:  Clin Vaccine Immunol       Date:  2011-01-12

2.  Biochemical and biophysical characterization of the sialyl-/hexosyltransferase synthesizing the meningococcal serogroup W135 heteropolysaccharide capsule.

Authors:  Angela Romanow; Thomas Haselhorst; Katharina Stummeyer; Heike Claus; Andrea Bethe; Martina Mühlenhoff; Ulrich Vogel; Mark von Itzstein; Rita Gerardy-Schahn
Journal:  J Biol Chem       Date:  2013-02-25       Impact factor: 5.157

3.  Seroprevalence of serum bactericidal antibodies against group W135 and Y meningococci in England in 2009.

Authors:  Caroline L Trotter; Helen Findlow; Ray Borrow
Journal:  Clin Vaccine Immunol       Date:  2011-12-21

Review 4.  Neisseria meningitidis: biology, microbiology, and epidemiology.

Authors:  Nadine G Rouphael; David S Stephens
Journal:  Methods Mol Biol       Date:  2012

5.  Molecular characterization of invasive meningococcal isolates from countries in the African meningitis belt before introduction of a serogroup A conjugate vaccine.

Authors:  Dominique A Caugant; Paul A Kristiansen; Xin Wang; Leonard W Mayer; Muhamed-Kheir Taha; Rasmata Ouédraogo; Denis Kandolo; Flabou Bougoudogo; Samba Sow; Laurence Bonte
Journal:  PLoS One       Date:  2012-09-27       Impact factor: 3.240

6.  Association between population prevalence of smoking and incidence of meningococcal disease in Norway, Sweden, Denmark and the Netherlands between 1975 and 2009: a population-based time series analysis.

Authors:  Gunnstein Norheim; Manish Sadarangani; Omar Omar; Ly-Mee Yu; Kåre Mølbak; Michael Howitz; Per Olcén; Margaretha Haglund; Arie van der Ende; Andrew J Pollard
Journal:  BMJ Open       Date:  2014-02-10       Impact factor: 2.692

7.  Global epidemiology of invasive meningococcal disease.

Authors:  Rabab Z Jafri; Asad Ali; Nancy E Messonnier; Carol Tevi-Benissan; David Durrheim; Juhani Eskola; Florence Fermon; Keith P Klugman; Mary Ramsay; Samba Sow; Shao Zhujun; Zulfiqar A Bhutta; Jon Abramson
Journal:  Popul Health Metr       Date:  2013-09-10

8.  Molecular characteristics and epidemiology of meningococcal carriage, Burkina Faso, 2003.

Authors:  Judith E Mueller; Lassana Sangaré; Berthe-Marie Njanpop-Lafourcade; Zekiba Tarnagda; Yves Traoré; Seydou Yaro; Raymond Borrow; Bradford D Gessner; Pierre Nicolas
Journal:  Emerg Infect Dis       Date:  2007-06       Impact factor: 6.883

9.  Meningococcal disease: changes in epidemiology and prevention.

Authors:  Qiuzhi Chang; Yih-Ling Tzeng; David S Stephens
Journal:  Clin Epidemiol       Date:  2012-09-19       Impact factor: 4.790

10.  Hyperinvasive Meningococci Induce Intra-nuclear Cleavage of the NF-κB Protein p65/RelA by Meningococcal IgA Protease.

Authors:  Anissa Besbes; Salomé Le Goff; Ana Antunes; Aude Terrade; Eva Hong; Dario Giorgini; Muhamed-Kheir Taha; Ala-Eddine Deghmane
Journal:  PLoS Pathog       Date:  2015-08-04       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.